Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8221682 | 0.86 | CYP1A2 (0.48) | CYP1A2CYP2C9CYP2C19ACHECYP1B1 | |
| SCHEMBL23581881 | 0.84 | CYP1A2 (0.49) | CYP1A2CYP2C9CYP2C19CYP1B1HTR2B | |
| SCHEMBL21605952 | 0.84 | CYP1A2 (0.49) | CYP1A2CYP2C9CYP2C19CYP1B1HTR2B | |
| SCHEMBL8268236 | 0.84 | CYP1A2 (0.49) | CYP1A2CYP2C9CYP2C19CYP1B1HTR2B | |
| SCHEMBL14528285 | 0.82 | CYP1B1 (0.48) | CYP1A2CYP2C9CYP2C19ACHECYP1B1 | |
| Hydrochloric Acid SCHEMBL28632936 | 0.82 | CYP1A2 (0.48) | CYP1A2CYP2C9CYP2C19CYP1B1HTR2B | |
| SCHEMBL1581709 | 0.82 | CYP1B1 (0.59) | CYP1A2CYP2C9CYP2C19ACHECYP1B1 | |
| SCHEMBL4294530 | 0.82 | ALDH1A1 (0.39) | CYP1A2CYP2C9CYP2C19ACHECYP1B1 | |
| SCHEMBL4294532 | 0.82 | ALDH1A1 (0.39) | CYP1A2CYP2C9CYP2C19ACHECYP1B1 | |
| SCHEMBL4294531 | 0.82 | ALDH1A1 (0.39) | CYP1A2CYP2C9CYP2C19ACHECYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699761-B1 | CB1 MODULATOR COMPOUNDS | LILLY CO ELI (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7595339-B2 | CB1 modulator compounds | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | ALLEN JENNIFER REBECCA | 2008-11-20 | — | — | US | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088018-A1 | Cb1 antagonist compounds | CNR1, CNR2, CHRNA5 | CYP1A2 2217/4885CYP2C9 2143/4885CYP2C19 1681/4885 |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | CNR1, CNR2, MAG | CYP1A2 2328/4885CYP2C9 2079/4885CYP2C19 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.